Arcturus, also known as XBB.1.16, has also attracted attention after reports linking it to what has been a rare COVID-19 symptom: pink eye.

Arcturus is responsible for a surge in COVID case counts in some parts of the world, including India, where itchy or “sticky” eyes have been most frequently reported in children, along with ...

Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...

New COVID-19 strain Arcturus may cause pink eye, LA Department of Public Health warns By Jack Hobbs Published April 30, 2023, 12:24 p.m. ET ...

XBB.1.16 Arcturus symptoms According to Schaffner, there have been “a slew of anecdotal reports" from doctors that the XBB.1.16 variant may be causing a few distinct and unusual symptoms ...

Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson ...

Arcturus, which is thought to be the most infectious and vaccine-resistant version of the virus yet, has already spread to 31 states, with California, New Jersey and New York emerging as hotspots.

SAN DIEGO, August 05, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease ...

Arcturus Therapeutics Announces Interim ARCT-021 Phase 1/2 Study Results, and Up to $220 Million in Additional Financial Commitments from Singapore ...

Arcturus was responsible for 9.6% of new infections for the week ending April 22, according to CDC estimates. That percentage is up from about 6% of cases the week before and about 3% two weeks ...

Stars are more colorful than you think! Patience will reveal them; head outside tonight to see summer’s multi-hued stars.